Clinical Research Directory

A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20

Sponsor: Pfizer

Summary

This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.

Official title: A RANDOMISED, PHASE 1, OPEN-LABEL, SINGLE-DOSE, STUDY TO EVALUATE THE PHARMACOKINETICS AND TOLERABILITY OF TILREKIMIG IN HEALTHY PARTICIPANTS WHEN CO-MIXED WITH RHUPH20 AS A SUBCUTANEOUS INJECTION

Key Details

Conditions

Interventions

Locations (1)